AR109085A1 - Uso de probióticos en el tratamiento y/o la prevención de la dermatitis atópica - Google Patents
Uso de probióticos en el tratamiento y/o la prevención de la dermatitis atópicaInfo
- Publication number
- AR109085A1 AR109085A1 ARP170101998A ARP170101998A AR109085A1 AR 109085 A1 AR109085 A1 AR 109085A1 AR P170101998 A ARP170101998 A AR P170101998A AR P170101998 A ARP170101998 A AR P170101998A AR 109085 A1 AR109085 A1 AR 109085A1
- Authority
- AR
- Argentina
- Prior art keywords
- lactis
- composition
- probiotic composition
- concentration
- composition according
- Prior art date
Links
- 239000006041 probiotic Substances 0.000 title abstract 9
- 235000018291 probiotics Nutrition 0.000 title abstract 9
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 12
- 230000000529 probiotic effect Effects 0.000 abstract 8
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 abstract 5
- 241001608472 Bifidobacterium longum Species 0.000 abstract 5
- 244000199866 Lactobacillus casei Species 0.000 abstract 5
- 244000005700 microbiome Species 0.000 abstract 5
- 235000013958 Lactobacillus casei Nutrition 0.000 abstract 2
- 229940009291 bifidobacterium longum Drugs 0.000 abstract 2
- 229940017800 lactobacillus casei Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- BSCMKVMJAHJNJW-UHFFFAOYSA-L 3-[2-carboxyethyl(dichloro)stannyl]propanoic acid Chemical compound OC(=O)CC[Sn](Cl)(Cl)CCC(O)=O BSCMKVMJAHJNJW-UHFFFAOYSA-L 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Fruits And Vegetables (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Non-Alcoholic Beverages (AREA)
- Dairy Products (AREA)
- Confectionery (AREA)
Abstract
Composición probiótica que comprende Bifidobacteriumanimalissubs.lactis (B. lactis), Bifidobacteriumlongum y Lactobacilluscasei, en particular, las cepas B. lactis CECT 8145, B. longum CETC 7347 y/o L. casei CECT 9104, en el tratamiento y/o prevención de la dermatitis atópica. Reivindicación 1: Composición probiótica que comprende Bifidobacteriumanimalissubs. lactis (B. lactis), Bifidobacteriumlongum y Lactobacilluscasei. Reivindicación 3: Composición probiótica según la reivindicación 1 ó 2, en donde la composición probiótica es una composición farmacéutica o una composición nutricional. Reivindicación 4: Composición probiótica según la reivindicación 3, en donde la composición farmacéutica comprende un vehículo y/o un excipiente farmacéuticamente aceptable. Reivindicación 10: Composición probiótica según cualquiera de las reivindicaciones 1 a 9, en donde la composición comprende, adicionalmente, un microorganismo seleccionado del grupo que consiste en Lactobacillussp., Streptococcussp., Bifidobacteriumsp., Saccharomycessp., Kluyveromycessp. y combinaciones de los mismos. Reivindicación 11: Composición probiótica según cualquiera de las reivindicaciones 1 a 10, en donde la concentración total de microorganismos de las cepas B. lactis, L. casei y B. longum en la composición es de entre 10³ y 10¹² ufc, preferiblemente, 10⁹ ufc. Reivindicación 12: Composición probiótica según cualquiera de las reivindicaciones 1 a 11, en donde la concentración de B. longum con respecto a la concentración total de microorganismos presentes en la composición es de, al menos, entre el 30% y el 40%; la concentración de B. lactis con respecto a la concentración total de microorganismos es de, al menos, entre el 30% y el 40%; y/o la concentración de L. casei con respecto a la concentración total de microorganismos es, al menos, de entre el 25 y el 35%.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382342.0A EP3272396A1 (en) | 2016-07-18 | 2016-07-18 | Use of probiotics in the treatment and/or prevention of atopic dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109085A1 true AR109085A1 (es) | 2018-10-24 |
Family
ID=56920674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101998A AR109085A1 (es) | 2016-07-18 | 2017-07-18 | Uso de probióticos en el tratamiento y/o la prevención de la dermatitis atópica |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20190282636A1 (es) |
| EP (2) | EP3272396A1 (es) |
| JP (1) | JP6998364B2 (es) |
| KR (1) | KR102390806B1 (es) |
| CN (1) | CN110214014A (es) |
| AR (1) | AR109085A1 (es) |
| AU (1) | AU2017299137B2 (es) |
| BR (1) | BR112019001116A2 (es) |
| CA (1) | CA3031002A1 (es) |
| DK (1) | DK3484585T3 (es) |
| EA (1) | EA201990086A1 (es) |
| ES (1) | ES2863398T3 (es) |
| HR (1) | HRP20210995T1 (es) |
| HU (1) | HUE055264T2 (es) |
| IL (1) | IL264282B1 (es) |
| MA (1) | MA44893B1 (es) |
| MX (1) | MX2019000821A (es) |
| MY (1) | MY194858A (es) |
| PE (1) | PE20190417A1 (es) |
| PH (1) | PH12019500123A1 (es) |
| PL (1) | PL3484585T3 (es) |
| PT (1) | PT3484585T (es) |
| RS (1) | RS62079B1 (es) |
| RU (1) | RU2757453C2 (es) |
| SI (1) | SI3484585T1 (es) |
| UA (1) | UA126664C2 (es) |
| WO (1) | WO2018015388A1 (es) |
| ZA (1) | ZA201900869B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109652349B (zh) * | 2019-02-25 | 2021-03-02 | 江南大学 | 一株能够缓解特应性皮炎的长双歧杆菌及其应用 |
| KR102136346B1 (ko) * | 2019-12-23 | 2020-07-22 | 주식회사 락토메이슨 | 한국인 영유아 유래 신규한 비피도박테리움 애니멀리스 락티스 lm1017을 유효성분으로 포함하는, 아토피 피부염의 예방 및 치료용 조성물 |
| EP3851115A1 (en) | 2020-01-15 | 2021-07-21 | Biopolis, S.L. | Probiotic composition for its use as an antioxidant |
| CN111296842B (zh) * | 2020-02-14 | 2021-01-05 | 赵一鸣 | 一种具有抗敏作用的益生菌组合物 |
| CN111528479A (zh) * | 2020-05-15 | 2020-08-14 | 深圳爱米基因科技有限责任公司 | 一种缓解特应性皮炎功能的益生菌和益生元组合物及应用 |
| EP3915537A1 (en) * | 2020-05-28 | 2021-12-01 | DuPont Nutrition Biosciences ApS | Bifidobacteria for preventing, reducing or treating skin aging |
| EP3973971A1 (de) * | 2020-09-28 | 2022-03-30 | Medice Arzneimittel Pütter GmbH & Co. KG | Probiotische pharmazeutische zusammensetzung |
| CN113430133B (zh) * | 2021-06-24 | 2023-06-23 | 微康益生菌(苏州)股份有限公司 | 一种能够缓解溃疡性结肠炎的复合益生菌、制备方法及其应用 |
| WO2023111270A1 (en) * | 2021-12-16 | 2023-06-22 | Biopolis, S. L. | Use of postbiotics in the treatment and/or prevention of anxiety disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004250337A (ja) * | 2003-02-18 | 2004-09-09 | Sunstar Inc | アレルギー疾患改善用製剤 |
| BRPI0516437A (pt) * | 2004-10-04 | 2008-09-02 | Oreal E Nestec S A L | utilização de uma quantidade eficaz de pelo menos um microorganismo, processo de tratamento cosmético, composição cosmética e/ou dermatológica e composição para absorção oral |
| CN101165162A (zh) * | 2007-09-30 | 2008-04-23 | 苏国权 | 一种益生菌活性制剂 |
| ES2343499B1 (es) * | 2007-12-24 | 2011-06-10 | Consejo Superior De Investigaciones Cientificas | Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten. |
| EP2251020A1 (en) * | 2009-05-11 | 2010-11-17 | Nestec S.A. | Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles |
| CN102802648A (zh) * | 2009-05-11 | 2012-11-28 | 雀巢产品技术援助有限公司 | 约氏乳杆菌La1 NCC533(CNCM I-1225)和免疫病症 |
| EP2228067B1 (de) * | 2010-02-22 | 2013-12-11 | LR Health & Beauty Systems GmbH | Probiotische Zusammensetzung und deren Verwendung |
| ES2389547B1 (es) * | 2010-12-07 | 2013-08-08 | Consejo Superior De Investigaciones Científicas (Csic) | Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas. |
| KR20130049554A (ko) * | 2011-11-04 | 2013-05-14 | 주식회사 쎌바이오텍 | 아토피 예방 또는 치료용 조성물 |
| ES2526986B1 (es) * | 2013-07-18 | 2015-11-02 | Biopolis, S.L. | Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas |
| CN104605277A (zh) * | 2013-11-05 | 2015-05-13 | 熊涛 | 一种功能性益生菌发酵果蔬粉的制备方法 |
| KR101545551B1 (ko) * | 2013-12-12 | 2015-08-19 | 주식회사한국야쿠르트 | 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물 |
| CN103705543A (zh) * | 2013-12-25 | 2014-04-09 | 广州华农大实验兽药有限公司 | 一种动物用粪源复方益生菌可溶性粉及其制备方法 |
| KR101724601B1 (ko) * | 2014-11-04 | 2017-04-10 | 주식회사 쎌바이오텍 | 아토피 예방 또는 치료용 조성물 |
-
2016
- 2016-07-18 EP EP16382342.0A patent/EP3272396A1/en not_active Withdrawn
-
2017
- 2017-07-18 JP JP2019503412A patent/JP6998364B2/ja active Active
- 2017-07-18 MA MA44893A patent/MA44893B1/fr unknown
- 2017-07-18 CN CN201780057072.1A patent/CN110214014A/zh active Pending
- 2017-07-18 ES ES17737847T patent/ES2863398T3/es active Active
- 2017-07-18 EP EP17737847.8A patent/EP3484585B1/en active Active
- 2017-07-18 MX MX2019000821A patent/MX2019000821A/es unknown
- 2017-07-18 UA UAA201901377A patent/UA126664C2/uk unknown
- 2017-07-18 AR ARP170101998A patent/AR109085A1/es unknown
- 2017-07-18 PE PE2019000223A patent/PE20190417A1/es unknown
- 2017-07-18 PL PL17737847T patent/PL3484585T3/pl unknown
- 2017-07-18 HU HUE17737847A patent/HUE055264T2/hu unknown
- 2017-07-18 CA CA3031002A patent/CA3031002A1/en active Pending
- 2017-07-18 PT PT177378478T patent/PT3484585T/pt unknown
- 2017-07-18 RS RS20210797A patent/RS62079B1/sr unknown
- 2017-07-18 MY MYPI2019000115A patent/MY194858A/en unknown
- 2017-07-18 SI SI201730813T patent/SI3484585T1/sl unknown
- 2017-07-18 IL IL264282A patent/IL264282B1/en unknown
- 2017-07-18 US US16/318,684 patent/US20190282636A1/en active Pending
- 2017-07-18 AU AU2017299137A patent/AU2017299137B2/en active Active
- 2017-07-18 DK DK17737847.8T patent/DK3484585T3/da active
- 2017-07-18 EA EA201990086A patent/EA201990086A1/ru unknown
- 2017-07-18 KR KR1020197004714A patent/KR102390806B1/ko active IP Right Grant
- 2017-07-18 RU RU2019104462A patent/RU2757453C2/ru active
- 2017-07-18 WO PCT/EP2017/068131 patent/WO2018015388A1/en unknown
- 2017-07-18 BR BR112019001116-1A patent/BR112019001116A2/pt unknown
-
2019
- 2019-01-17 PH PH12019500123A patent/PH12019500123A1/en unknown
- 2019-02-11 ZA ZA2019/00869A patent/ZA201900869B/en unknown
-
2021
- 2021-06-23 HR HRP20210995TT patent/HRP20210995T1/hr unknown
-
2022
- 2022-08-15 US US17/888,317 patent/US20230048705A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109085A1 (es) | Uso de probióticos en el tratamiento y/o la prevención de la dermatitis atópica | |
| ES2477882T3 (es) | Probióticos, IgA secretora e infección | |
| AR107921A1 (es) | Uso de probióticos en el tratamiento y/o la prevención de la enfermedad de la psoriasis | |
| ES2561253T3 (es) | Bacterias probióticas que tienen actividad antioxidante y uso de las mismas | |
| MX2011012069A (es) | Micro-organismos no-replicantes y su efecto inmuno estimulador. | |
| AR035761A1 (es) | Bacterias de acido lactico como agentes para tratar y prevenir la alergia | |
| CL2018001936A1 (es) | Nueva cepa bacteriana probiótica de lactobacillus plantarum y composiciones y usos de la misma en el tratamiento de la inflamación. | |
| MY171618A (en) | Strain of lactobacillus as probiotic | |
| IT201600091033A1 (it) | Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti. | |
| MX2017007654A (es) | Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas. | |
| CL2017001706A1 (es) | Empleo de probióticos en el incremento de la fertilidad masculina. | |
| MX2022008666A (es) | Composicion probiotica para su uso como antioxidante. | |
| AR120748A1 (es) | Preparación que comprende cepas probióticas y proceso para identificar consorcios de cepas probióticas adecuadas para la degradación del gluten | |
| JP2016003187A5 (es) | ||
| Tehrani et al. | The effect of some lactobacillus species (probiotics) on biofilm inhibition in Enterococcus faecium | |
| UA127306U (uk) | Комплексний пробіотичний препарат | |
| MX2020007906A (es) | Composicion que comprende nuevas cepas de lactobacillus salivarius y metodo para la prevencion y el tratamiento de otitis e infecciones respiratorias de vias altas. | |
| CO2023004516A2 (es) | Composiciones probióticas para el tratamiento del acné | |
| AR096754A1 (es) | Composición de solución de rehidratación oral que contiene probióticos | |
| WANG | The screening of Beauveria bassiana strain with high virulence to Hylobitelus xiaoi Zhang | |
| Basmechi et al. | ANTIBIOTIC RESISTANCE OF LACTIC ACID BACTERIA ISOLATED FROM HOME-MADE IranIAN DAIRY PRODUCTS | |
| Dallal et al. | ANTAGONISTIC ACTIVITY OF LACTOBACILLUS STRAINS ISOLATED FROM FECAL MICROFLORA OF HEALTHY BREAST-FED INFANTS AGAINST SHIGELLA FLEXNERI | |
| AR101272A1 (es) | Leche fermentada para la prevención y/o tratamiento de las infecciones intestinales en teneros y procedimientos | |
| PL406051A1 (pl) | Zastosowanie kompozycji probiotycznej | |
| PL416202A1 (pl) | Kompozycja farmaceutyczna zawierająca połączenie kwasu hialuronowego, roślinnych fitoestrogenów oraz szczepów probiotycznych z rodzaju Lactobacillus do aplikacji waginalnej |